Suchergebnisse - Toshiyuki Tamai
- Treffer 1 - 10 von 10
-
1
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses von Toshiyuki Tamai, Seiichi Hayato, Seiichiro Hojo, Takuya Suzuki, Takuji Okusaka, Kenji Ikeda, Hiromitsu Kumada
Veröffentlicht 2017Artigo -
2
-
3
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma von Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe, Yukio Osaki, Masafumi Ikeda, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Seiichi Hayato, Kiwamu Okita, Hiromitsu Kumada
Veröffentlicht 2016Artigo -
4
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial von Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto
Veröffentlicht 2024Artigo -
5
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma von Arndt Vogel, Catherine Frenette, Max W. Sung, Bruno Daniele, Ari David Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo
Veröffentlicht 2021Artigo -
6
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies von Robert J. Motzer, Matthew H. Taylor, T.R. Jeffry Evans, Takuji Okusaka, Hilary Glen, Gregory M. Lubiniecki, Corina E. Dutcus, Alan D. Smith, Chinyere E. Okpara, Ziad Hussein, Seiichi Hayato, Toshiyuki Tamai, Vicky Makker
Veröffentlicht 2022Revisão -
7
REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset von Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda, Namiki Izumi, Ryosuke Tateishi, Masafumi Ikeda, Hiroshi Aikata, Yasunori Kawaguchi, Yoshiyuki Wada, Kazushi Numata, Yoshitaka Inaba, Ryoko Kuromatsu, Masahiro Kobayashi, Takuji Okusaka, Toshiyuki Tamai, Chifumi Kitamura, Kenichi Saito, Katsuya Haruna, Kiwamu Okita, Hiromitsu Kumada
Veröffentlicht 2019Artigo -
8
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study von Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos López, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong‐Won Park, D. Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni
Veröffentlicht 2022Artigo -
9
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study von Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean‐Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang‐Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, T.R. Jeffry Evans
Veröffentlicht 2021Artigo -
10
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial von Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann‐Lii Cheng
Veröffentlicht 2018Artigo
Suchwerkzeuge:
Ähnliche Schlagworte
Internal medicine
Medicine
Oncology
Lenvatinib
Hepatocellular carcinoma
Sorafenib
Gastroenterology
Adverse effect
Carcinoma
Clinical trial
Pharmacokinetics
Cancer
Cmax
Pharmacodynamics
Pharmacology
Thyroid cancer
Abdominal surgery
Area under the curve
Clinical endpoint
Confidence interval
Environmental health
Hazard ratio
Hepatology
Liver function
Overall survival
Phases of clinical research
Population
Post-hoc analysis
Renal cell carcinoma
Renal function